Impact of Granulocyte Colony-Stimulating Factor on Chemotherapy for Lung Cancer
Author Information
Author(s): M Fukuoka, N Masuda, S Negoro, K Matsui, T Yana, S Kudoh, Y Kusunoki, M Takada, M Kawahara, M Ogawara, N Kodama, K Kubota, K Furuse
Primary Institution: Osaka Prefectural Habikino Hospital; National Kinki Central Hospital
Hypothesis
Does the addition of granulocyte colony-stimulating factor (rhG-CSF) to CODE chemotherapy improve survival in patients with extensive-stage small-cell lung cancer?
Conclusion
The use of rhG-CSF with CODE chemotherapy significantly prolongs survival and increases dose intensity in patients with extensive-stage small-cell lung cancer.
Supporting Evidence
- Patients receiving rhG-CSF had a median survival of 59 weeks compared to 32 weeks for those who did not.
- The overall response rate was 97% in the rhG-CSF group versus 84% in the control group.
- Patients treated with rhG-CSF experienced a significant increase in dose intensity of chemotherapy drugs.
Takeaway
This study found that giving a special medicine called rhG-CSF along with chemotherapy helps people with a type of lung cancer live longer and get more medicine without getting too sick.
Methodology
Patients were randomized to receive CODE chemotherapy alone or with rhG-CSF, and their survival and response rates were compared.
Potential Biases
Potential biases in patient selection and treatment allocation could affect the results.
Limitations
The study may not be generalizable to all patients with small-cell lung cancer due to specific inclusion criteria.
Participant Demographics
Patients aged 18-75 with extensive-stage small-cell lung cancer, including both males and females.
Statistical Information
P-Value
0.004
Confidence Interval
95% CI, 45.6-90.9 for rhG-CSF group; 95% CI, 24.4-41.4 for control group
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website